StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the stock.

A number of other research analysts have also weighed in on ONCT. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Securities reissued a “market perform” rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, HC Wainwright decreased their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $1.45 on Tuesday. The stock has a market capitalization of $4.29 million, a PE ratio of -0.12 and a beta of 1.39. Oncternal Therapeutics has a one year low of $1.32 and a one year high of $13.14. The business’s fifty day moving average price is $4.66 and its 200-day moving average price is $7.11.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.03) by $0.14. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same period in the prior year, the firm earned ($3.00) earnings per share. As a group, equities analysts expect that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned about 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.